Ceva launches TULAVEN - a new addition to its range of treatments for BRD - Veterinary Practice
Your browser is out-of-date!

Update your browser to view this website correctly. Update my browser now

×

Ceva launches TULAVEN – a new addition to its range of treatments for BRD

TULAVEN complements Ceva’s extensive BRD portfolio of products

Ceva Animal Health has extended its comprehensive range of treatments for Bovine Respiratory Disease (BRD) with the launch of TULAVEN 100mg/ml.

Containing the well-known and trusted active ingredient, tulathromycin, TULAVEN is licensed for the treatment and metaphylaxis (as per the SPC, presence of the disease in the herd should be established before starting metaphylactic treatment) of BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis. It joins Ceva’s popular and extensive range of BRD treatments, which includes ZELERIS, FLORKEM, MELOXIDYL and ALLEVINIX. This, in addition to Ceva-owned Ridgeway Biologicals which has the facility to develop autogenous vaccines, enhances Ceva’s expertise in the treatment of BRD.

TULAVEN can also be used to treat Infectious Bovine Keratoconjunctivitis (IBK) associated with Moraxella bovis as well as Porcine Respiratory Disease Complex (PRDC) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis and Bordetella bronchiseptica.

To enhance Ceva’s range of sheep products, TULAVEN is licensed to treat the early stages of infectious pododermatitis (foot rot) in sheep associated with virulent Dichelobacter nodosus.

TULAVEN is the first and only tulathromycin available in innovative CLAS (Ceva Layered Anti Shatter) vials. These shock resistant plastic vials have 33 per cent less impact on the environment from cradle to grave than glass vials. With 99 percent of farmers preferring to use CLAS vials over glass, the easy to use, practical and eco-friendly CLAS vials are not only robust and shock resistant for less breakage, spillage and losses, but the ergonomic “grip groove” ensures easier handling, while the light weight material makes the vials easier to transport.

Cuneyt Seckin, managing director of Ceva Animal Health UK and Ireland, says: “Ceva has been developing its expertise in the treatment of BRD for many years, with a wide range of treatment options and autogenous vaccines available for vets. The launch of TULAVEN is the next addition to this range, enabling us to offer even more support to vets and farmers.”

Peter Keyte, ruminant business unit manager at Ceva Animal Health, adds: “We are delighted to add the trusted and affordable tulathromycin, TULAVEN, to our range. It complements our extensive BRD portfolio of products, including ZELERIS, FLORKEM, MELOXIDYL and ALLEVINIX, most of which will be available in CLAS shatterproof vials from 2021, making them ideal for farm conditions.”

For further information on TULAVEN please contact your local Ceva territory manager, call Ceva on 01494 781510 or email cevauk@ceva.com.

Veterinary Practice

Veterinary Practice is an online knowledge and information hub for veterinary professionals across all specialties. It provides reliable, useful and interesting content, written by expert authors and covering small animal, large animal, equine and practice management sectors of the veterinary surgeon and nursing professions.


More from this author

Have you heard about our
IVP Membership?

A wide range of veterinary CPD and resources by leading veterinary professionals.

Stress-free CPD tracking and certification, you’ll wonder how you coped without it.

Discover more